WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation [see Warnings and Precautions (5.1), Drug Interactions (7.1)].
The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with a n increased frequency of serious adverse outcomes.
Before prescribing Midazolam Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [see Warnings and Precautions (5.2)]. The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose.
Although Midazolam Injection is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2)], if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of Midazolam Injection may precipitate acute withdrawal reactions, which can be life-threatening. For patients using Midazolam Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue Midazolam Injection [see Warnings and Precautions (5.3)].
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS See full prescribing information for complete boxed warning. Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation.
(5.1, 7.1) The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing Midazolam Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction. (5.2) Although Midazolam Injection is indicated only for intermitt ent use (1, 2), if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of Midazolam Injection may precipitate acute withdrawal reactions, which can be lifethreatening.
For patients using Midazolam Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue Midazolam Injection. (5.3)
Use: Labeled indications
- Midazolam Injection is indicated for the treatment of status epilepticus in adults.
Full indications and usage US FDA label
Midazolam Injection is indicated for the treatment of status epilepticus in adults. Midazolam Injection is a benzodiazepine indicated for the treatment of status epilepticus in adults. (1)
Contraindications
Midazolam Injection is contraindicated in patients with a known hypersensitivity to midazolam. Hypersensitivity to midazolam. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
Recommended Dose The recommended dose of Midazolam Injection is a single 10 mg dose, administered by intramuscular injection [see Dosage and Administration (2.2)]. Important Administration Instructions Midazolam Injection should be administered by trained personnel who have had adequate training in the recognition and treatment of status epilepticus and first aid/basic airway management.
Midazolam Injection is for intramuscular use only as a single dose. Inject in the mid-outer thigh (vastus lateralis muscle) using the prefilled autoinjector. The Midazolam autoinjector can inject through clothing. Move all objects from in and around the patient’s clothing that may interfere with the injection. For people who do not have a lot of fat at the mid-outer thigh, bunch up the thigh at the injection site to provide a thicker area for administration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit [see Dosage Forms and Strengths (3)]. Refer to the illustrated Midazolam Injection Instructions for Use for autoinjector administration instructions. Monitoring After administration of Midazolam Injection, continuous monitoring of respiratory and cardiac function is recommended until the patient is stabilized.
Serious and life-threatening cardiorespiratory adverse reactions, such as hypoventilation, airway obstruction, apnea, and hypotension have been reported with the use of midazolam. Patients should be monitored in a setting that allows for immediate access to resuscitative drugs. Appropriate resuscitation equipment and personnel trained in their use and skilled in airway management should be available [see Warnings and Precautions (5.4), Adverse Reactions (6.1)].
Observation for signs of cardiorespiratory depression is particularly important in patients with chronic obstructive pulmonary disease (COPD), patients 60 or more years of age, and patients who have received concomitant narcotics or other central nervous system (CNS) depressants. The recommended dose is a single 10 mg dose, administered by intramuscular injection using the prefilled autoinjector.
(2.1) Inject in the mid-outer thigh (vastus lateralis muscle). (2.2) Continuous monitoring of respiratory and cardiac function is recommended. (2.3)
Dosing: Altered kidney function
Patients with Renal Impairment Patients with renal impairment may have longer elimination half-lives for midazolam and its metabolites [see Use in Specific Populations (8.6)]. Midazolam and 1-hydroxy-midazolam pharmacokinetics were compared between 6 intensive care unit (ICU) patients who developed acute renal failure (ARF) and a control group of subjects with normal renal function.
Midazolam was administered as an IV infusion (5 to 15 mg/hour). Midazolam clearance was reduced (1.9 versus 2.8 mL/min/kg), and the half-life was prolonged (7.6 hours versus 13 hours) in the ARF patients. The renal clearance of the 1-hydroxy-midazolam glucuronide was prolonged in the ARF group (4 versus 136 mL/min), and the half-life was prolonged (12 hours versus >25 hours).
Plasma levels accumulated in all ARF patients to about ten times that of the parent drug. The relationship between accumulating metabolite levels and prolonged sedation is unclear. In a study of chronic renal failure patients (n=15) receiving a single IV dose of midazolam, there was a 2-fold increase in the clearance and volume of distribution, but the half-life remained unchanged.
Metabolite levels were not studied.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Solution for injection: 1 mg/mL, 5 mg/mL
- ) solution for injection: 1 mg/mL (5 mg/5 mL, 5 mg/mL (15 mg/3 mL, 5 mg/mL (5 mg/1 mL
- ) solution for injection/infusion: 1 mg/mL (5 mg/5 mL
- Film-coated tablet: 15 mg
- Solution for injection/infusion: 5 mg/mL
Registered products in the Philippines
28 products registered with the Food and Drug Administration (FDA) Philippines list Midazolam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products28
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BenzosedMidazolam | 5 mg/mL Solution for Injection (IM/IV)Glass brown x 3 mL and 10 mL (Box of 5's) | RxVAT-exempt | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines IncTrader: N/A | DR-XY49358 | Apr 7, 2030 | |
DormicumMidazolam | 1 mg/mL (5 mg/5 mL) Solution for Injection (IM/IV)5mL clear and colorless glass ampoule (Box of 10's) | RxVAT-exempt | CenexiFrance | ZUELLIG PHARMA CORPORATIONTrader: CHEPLAPHARM ARZNEIMITTEL GMBH | DR-XY28582 | Apr 28, 2028 | |
DormicumMidazolam | 15 mg Film-Coated TabletTransparent Duplex Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Recipharm Leganes SLUSpain | Zuellig Pharma CorporationTrader: Cheplapharm Arzneimittel GmbH | DR-XY41657 | Feb 5, 2028 | |
DormicumMidazolam | 5mg/mL Solution for Injection (IM/IV)1 mL clear and colorless glass ampoule (Box of 10's) | RxVAT-exempt | CenexiFrance | Zuellig Pharma CorporationTrader: Cheplapharm Arzneimittel GmbH | DR-XY28584 | Apr 28, 2028 | |
DormizinMidazolam (as Hydrochloride) | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 3 mL (Box of 10's) | RxVAT-exempt | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil. Pharmawealth, Inc.Trader: Oboi Laboratories | DR-XY48346 | Sep 12, 2027 | |
DormizinMidazolam (as hydrochloride) | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 3 mL (Box of 10's) | RxVAT-exempt | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil. Pharmawealth, Inc.Trader: Oboi Laboratories | DRP-13864 | Sep 12, 2027 | |
DormizinMidazolam (as Hydrochloride) | 5 mg/mL (5 mg/ 1 mL) Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil. Pharmawealth, Inc.Trader: Laboratories | DRP-13259 | Jan 18, 2028 | |
DormizolMidazolam | 5 mg/mL Solution for Injection (IM/IV)USP Type I Clear and Colorless Glass Ampoule x 1 mL and 3 mL (Box of 10's) | RxVAT-exempt | Harson LaboratoriesIndia | Phil. Pharmawealth, Inc. | DR-XY41527 | Mar 18, 2028 | |
HypmidMidazolam (as hydrochloride) | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV/Rectal)Ph. Eur. Type I clear and colorless glass ampoule (Box of 5's) | RxVAT-exempt | Mefar Ilac Sanayii A.S.Turkey | Ambica International CorporationTrader: Pharmada İlaç San. Ve Tic A.Ş | DRP-10702 | Nov 10, 2031 | |
Hypnotic and Sedative (Benzodiazepine derivative)Midazolam | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV)3mL clear and colorless glass ampoule (Box of 5's) | RxVAT-exempt | CenexiFrance | ZUELLIG PHARMA CORPORATIONTrader: CHEPLAPHARM ARZNEIMITTEL GMBH | DR-XY28583 | Apr 28, 2028 | |
HypozamMidazolam | 1 mg/mL Solution for Injection (IM/IV)USP Type III glass ampoule in 3 mL and 5 mL (Box of 10's) | RxVAT-exempt | Brookes Pharma (Private) LimitedPakistan | Sahar International Trading, Inc. | DR-XY38463 | Sep 14, 2030 | |
MidaGetMidazolam | 5mg/mL (15mg/3mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 3mL (Box of 5's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-17637 | Feb 10, 2031 | |
MidamarcMidazolam | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV/Rectal)Type I colorless glass ampoule x 3 mL (Box of 10's) | RxVAT-exempt | HBM Pharma s.r.o.Slovak Republic | Marcburg Philippines Inc.Trader: Akciju sabiedriba "Kalceks" | DR-XY48703 | Apr 14, 2028 | |
MidamarcMidazolam | 5 mg/mL Solution for Injection (I.M./I.V./Rectal) | RxVAT-exempt | HBM Pharma S.R.O.Slovak | Marcburg Philippines Inc.Trader: Akciju Sabiedrida Kalceks" """ | DR-XY49634 | Feb 10, 2031 | |
MidamicumMidazolam (as hydrochloride) | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV/Rectal)Ph. Eur. Type I clear and colorless glass ampoule (Box of 5's) | RxVAT-exempt | Mefar Ilac Sanayii A.S.Turkey | Marcburg Philippines Inc.Importer: Ambica International CorporationTrader: Pharmada İlaç San. Ve Tic A.Ş | DRP-10703 | Nov 10, 2031 | |
MidamicumMidazolam (as hydrochloride) | 5 mg/mL Solution for Injection (I.M./I.V./Rectal)1 mL Type I clear colorless Glass Ampoule (Box of 5's) | RxVAT-exempt | Mefar Ilac Sanayii A.S.Turkey | Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S. | DRP-13594 | Mar 14, 2028 | |
MidazofilMidazolam (as hydrochloride) | 5 mg/mL Solution for Injection (I.M./I.V./Rectal)1 mL Type I clear colorless glass ampoule (Box of 5's) | RxVAT-exempt | Mefar Ilac Sanayii A.STurkey | Filadams Pharma, Inc.Importer: Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic. A.S. | DRP-13594-01 | Mar 14, 2028 | |
MidazolexMidazolam | 1 mg/mL (5 mg/5 mL) Solution for Injection (I.M/I.V.)Type I Clear Colorless Glass Ampoule x 5 mL (Box of 10's) | RxVAT-exempt | Myungmoon Pharm. Co., Ltd.Korea | Delex Pharma International, Inc. | DRP-4892 | Apr 5, 2028 | |
MidazolexMidazolam | 5 mg/mL (15 mg/3 mL) Solution for Injection (IM/IV)3 mL Type I Clear Colorless Glass Ampoule x 5 per Plastic Tray (Box of 5's) | RxVAT-exempt | — | DELEX PHARMA INTERNATIONAL, INC. | DRP-5024 | Apr 5, 2028 | |
MinodazMidazolam (as hydrochloride) | 5 mg/mL Solution for Injection (IM/IV)Type I Amber Glass Vial with grey bromo butyl rubber stopper and flip off seal x 10 mL (Box of 10's) | RxVAT-exempt | Swiss Parenterals Ltd.India | AGlobal Care, Inc. | DRP-16734 | Jul 1, 2030 | |
MizamMidazolam | 1 mg/mL (5 mg/5 mL) Solution for Injection (I.M./I.V.)5 mL USP Type III Clear glass ampoule with white ring in plastic tray (Box of 10's) | RxVAT-exempt | Global Pharmaceuticals (Pvt) Ltd.Pakistan | Surestep Pharmaceuticals, Inc. | DR-XY40893 | Aug 2, 2027 | |
NoneMidazolam (as hydrochloride) | 1mg/mL Solution for Injection (I.M./I.V.)USP Type III Amber Glass Vial x 5mL and 10mL Box of 1's | RxVAT-exempt | Swiss Parenterals Pvt. Ltd.India | Endure Medical, Inc. | DR-XY41312 | Nov 5, 2027 | |
SedacumMidazolam Hydrochloride | 5 mg/mL Solution for Injection (IM/IV)5 mL USP Type I Clear Glass Ampoule x 3 mL (Box of 5's) | RxVAT-exempt | PT Ferron Par PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica | DRP-8768 | Jun 13, 2028 | |
SedazolamMidazolam | 5mg/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule with White Ring on Neck x 3 mL (Box of 5's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc.Trader: N/A | DRP-18944 | Oct 6, 2031 | |
SedozMidazolam | 1mg/mL Solution for Injection (IM/IV)Blister pack of 1 glass vial with light blue flip off seal (Box of 10s) | RxVAT-exempt | Baxter Pharmaceuticals India Private LimitedIndia | Macropharma CorporationImporter: Baxter Healthcare Philippines Inc. | DR-XY30768 | May 23, 2031 | |
SezolamMidazolam | 5 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 3 mL (Box of 5's); USP Type I Amber Glass Ampoule x 3 mL (Box of 10's); USP Type I Amber Glass Ampoule x 3 mL (Box of 25's) | RxVAT-exempt | Baxter Pharmaceutical India Private LimitedIndia | Macropharma CorporationImporter: Baxter Healthcare Philippines Inc | DRP-6984 | Dec 5, 2028 | |
(no brand name)Midazolam (as hydrochloride) | 1 mg/mL (5 mg/5 mL) Solution for Injection/Infusion (IM/IV/Rectal)Type I clear and colorless glass ampoule x 5 mL (Box of 10's) | RxVAT-exempt | Siegfried Hameln GmbHGermany | Enlife Global Inc. | DRP-11542 | May 5, 2027 | |
(no brand name)Midazolam (as hydrochloride) | 5 mg/mL Solution for Injection/Infusion (IM/IV/Rectal)Type I clear colorless glass ampoule. (Box of 10's x 1 mL; Box of 10's x 3 mL) Type I clear colorless glass ampoule (Box of 5's x 1 mL; Box of 5's x 3 mL) | RxVAT-exempt | Siegfried Hameln GmbHGermany | Enlife Global Inc. | DRP-11545 | Jun 16, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
Injection: 10 mg/0.7 mL of a sterile, clear, colorless to slightly yellow liquid solution in a single-dose prefilled autoinjector. Injection: 10 mg/0.7 mL in a single-dose pre-filled autoinjector. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including Midazolam Injection, and opioids may result in profound sedation, respiratory depression, coma, and death. If a decision is made to use midazolam concomitantly with opioids, monitor patients closely for respiratory depression and sedation [see Drug Interactions (7.1)].
Trained personnel administering Midazolam Injection must have the skills necessary to manage serious cardiorespiratory adverse reactions, including skills in airway management. Abuse, Misuse, and Addiction The use of benzodiazepines, including Midazolam Injection, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death.
Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death [see Drug Abuse and Dependence (9.2)]. Before prescribing Midazolam Injection and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
Use of Midazolam Injection, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of Midazolam Injection along with monitoring for signs and symptoms of abuse, misuse, and addiction. Do not exceed the recommended dosing frequency; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug.
If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate. Dependence and Withdrawal Reactions After Use of Midazolam Injection More Frequently Than Recommended For patients using Midazolam Injection more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue Midazolam Injection (a patient-specific plan should be used to taper the dose).
Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use. Acute Withdrawal Reactions The continued use of benzodiazepines may lead to clinically significant physical dependence.
Although Midazolam Injection is indicated only for intermittent use [see Indications and Usage (1) and Dosage and Administration (2)], if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of Midazolam Injection, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [see Drug Abuse and Dependence (9.3)]. Protracted Withdrawal Syndrome In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months [see Drug Abuse and Dependence (9.3)].
Risks of Cardiorespiratory Adverse Reactions Serious cardiorespiratory adverse reactions have occurred after administration of midazolam. These have included respiratory depression, airway obstruction, oxygen desaturation, apnea, respiratory arrest and/or cardiac arrest, sometimes resulting in death or permanent neurologic injury.
There have also been rare reports of hypotensive episodes requiring treatment during or after diagnostic or surgical manipulations, particularly in patients with hemodynamic instability. Hypotension occurs more frequently in patients premedicated with a narcotic. The danger of hypoventilation, airway obstruction, or apnea is greater in elderly patients and those with chronic disease states or decreased pulmonary reserve [see Use in Specific Populations (8.5, 8.7)]; patients with COPD are highly sensitive to the respiratory depressant effect of midazolam.
Midazolam Injection should be administered with caution to patients in shock or coma with depression of vital signs. Trained personnel administering Midazolam Injection must have the skills necessary to manage serious cardiorespiratory adverse reactions, including skills in airway management. Other Adverse Reactions Reactions such as agitation, involuntary movements (including tonic/clonic movements and muscle tremor), hyperactivity, and combativeness have been reported with midazolam when used for sedation.
These reactions may be caused by inadequate or excessive dosing or improper administration of midazolam; however, consideration should be given to the possibility of cerebral hypoxia or true paradoxical reactions. Agitation also occurred in the randomized controlled clinical study of midazolam injection in patients with status epilepticus [see Adverse Reactions (6.1)].
Risks from Concomitant Use of Central Nervous System Depressants Concomitant use of barbiturates, alcohol or other central nervous system depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. Midazolam Injection should be administered with caution to patients in acute alcohol intoxication with depression of vital signs.
Narcotic premedication also depresses the ventilatory response to carbon dioxide stimulation. The efficacy and safety of midazolam in clinical use are functions of the dose administered, the clinical status of the individual patient, and the use of concomitant medications capable of depressing the central nervous system (CNS).
Anticipated effects range from mild sedation to deep levels of sedation virtually equivalent to a state of general anesthesia where the patient may require external support of vital functions. Trained personnel administering Midazolam Injection must have the skills necessary to manage serious cardiorespiratory adverse reactions, including skills in airway management.
For information regarding withdrawal, see Drug Abuse and Dependence (9.3). Impaired Cognitive Function Midazolam is associated with a high incidence of partial or complete impairment of recall for several hours following an administered dose. Gross tests of recovery from the effects of midazolam cannot be relied upon to predict reaction time under stress.
It is recommended that no patient operate hazardous machinery or a motor vehicle until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits. Glaucoma Benzodiazepines, including Midazolam Injection, can increase intraocular pressure in patients with glaucoma. Measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam; patients with glaucoma have not been studied.
Patients with open-angle glaucoma may need to have their ophthalmologic status evaluated following treatment with Midazolam Injection. Midazolam Injection is not recommended in patients with narrow-angle glaucoma. Neonatal Sedation and Withdrawal Syndrome Use of Midazolam Injection late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate [see Use in Specific Populations (8.1)].
Monitor neonates exposed to Midazolam Injection during pregnancy or labor for signs of sedation and monitor neonates exposed to Midazolam Injection during pregnancy for signs of withdrawal; manage these infants accordingly. Risks of Cardiorespiratory Adverse Reactions: Serious cardiorespiratory adverse reactions have occurred, sometimes resulting in death or permanent neurologic injury, after administration of midazolam.
(5.4) Other Adverse Reactions: Agitation can occur. (5.5) Risks from Concomitant Use of Central Nervous System (CNS) Depressants: May increase risk of hypoventilation, airway obstruction, desaturation, or apnea, and may contribute to profound and/or prolonged drug effect. Practitioners administering Midazolam Injection must have the skills necessary to manage serious cardiorespiratory adverse reactions, including skills in airway management.
(5.6) Impaired Cognitive Function: Because of partial or complete impairment of recall, patients should not operate hazardous machinery or a motor vehicle until drug effects have subsided. (5.7) Glaucoma: Patients with open-angle glaucoma may need to have their ophthalmologic status evaluated following treatment with Midazolam Injection.
Midazolam injection is not recommended in patients with narrow-angle glaucoma. (5.8) Neonatal Sedation and Withdrawal Syndrome: Midazolam Injection use during pregnancy can result in neonatal sedation and/or neonatal withdrawal. (5.9, 8.1)
Drug interactions
Drug interactions (US label) US FDA label
Effect of Concomitant Use of Benzodiazepines and Opioids The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors.
When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids. Monitor patients closely for respiratory depression and sedation. Other CNS Depressants and Alcohol The sedative effect of Midazolam Injection is accentuated by concomitantly administered medication that depresses the central nervous system, particularly opioids (e.g., morphine, meperidine, and fentanyl), secobarbital, and droperidol, and also by alcohol [see Warnings and Precautions (5.1, 5.4, 5.6)].
Cytochrome P450-3A4 Inhibitors Caution is advised when Midazolam Injection is administered concomitantly with drugs that are known to inhibit the P450-3A4 enzyme system (e.g., cimetidine, erythromycin, diltiazem, verapamil, ketoconazole, and itraconazole). These drug interactions may result in prolonged sedation caused by a decrease in plasma clearance of midazolam [see Clinical Pharmacology (12.3)].
Benzodiazepines and Opioids: Risk of respiratory depression is increased. (7.1) Other CNS Depressants and Alcohol: Sedative effect of midazolam is increased. (7.2) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7.3)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism In vitro studies with human liver microsomes indicate that the biotransformation of midazolam is mediated by the cytochrome P450-3A4 (CYP3A4).
Drug Interaction Studies CYP3A4 Inhibitors Drugs that inhibit the activity of CYP3A4 may inhibit midazolam clearance and elevate midazolam concentrations [see Drug Interactions (7.3)].
CYP3A4 Inducers Drugs that induce the activity of CYP3A4 may increase midazolam clearance and decrease midazolam concentrations.
Adverse reactions
Adverse reactions (US label) US FDA label
The following serious adverse reactions are discussed in greater detail in other sections: Risks from Concomitant Use with Opioids [see Warnings and Precautions (5.1)] Abuse, Misuse, and Addiction [see Warnings and Precautions (5.2)] Dependence and Withdrawal Reactions After Use of Midazolam Injection More Frequently Than Recommended [see Warnings and Precautions (5.3)] Risks of Cardiorespiratory Adverse Reactions [see Warnings and Precautions (5.4)] Other Adverse Reactions [see Warnings and Precautions (5.5)] Risks from Concomitant Use of Central Nervous System Depressants [see Warnings and Precautions (5.6)] Impaired Cognitive Function [see Warnings and Precautions (5.7)] Glaucoma [see Warnings and Precautions (5.8)] Neonatal Sedation and Withdrawal Syndrome [see Warnings and Precautions (5.9)] Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of Midazolam Injection has been established by data from an adequate and well-controlled study of a different midazolam injection in adult patients with status epilepticus [see Clinical Studies (14)].
Below is a display of the adverse reactions of midazolam injection in this adequate and well-controlled study. Adverse Reactions in the Controlled Study of Intramuscular Midazolam in Patients with Status Epilepticus In a double-blind, randomized, active-controlled clinical study, 448 patients were assigned to receive intramuscular (IM) midazolam via an autoinjector, and 445 were assigned to receive intravenous (IV) lorazepam.
Approximately 45% of patients were female, and the mean age was 43 years. Patients were administered treatment by a healthcare professional (e.g., paramedic) prior to arrival at a hospital. Table 1 lists the adverse reactions occurring in 2% or more of the IM midazolam-treated patients and at a rate greater than the IV lorazepam-treated patients.
Table 1 Adverse Reactions in 2% or More of IM Midazolam-Treated Patients and More Frequent than in IV Lorazepam-Treated Patients in Out of Hospital Treatment of Status Epilepticus Adverse Reactions in Other Midazolam Studies Midazolam Injection is only indicated for status epilepticus, but for uses other than that for which Midazolam Injection is indicated, fluctuations in vital signs were the most frequently seen findings following parenteral administration of midazolam in adults, and included decreased tidal volume and/or respiratory rate decrease [11% of patients following intramuscular administration], as well as variations in blood pressure and pulse rate. The majority of serious adverse effects, particularly those associated with oxygenation and ventilation, have been reported when midazolam was administered with other medications capable of depressing the CNS.
The incidence of such events was higher in patients undergoing procedures involving the airway without the protective effect of an endotracheal tube (e.g., upper endoscopy and dental procedures). The following additional adverse reactions were reported after intramuscular administration in adults: Headache (1.3%), and local effects at the IM injection site including pain (3.7%), induration (0.5%), redness (0.5%), and muscle stiffness (0.3%).
The most common adverse reactions (incidence >3%) in clinical trials in patients with status epilepticus were upper airway obstruction, agitation, and pyrexia. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Rafa Laboratories, Ltd. at 1-386-418-7911 or FDA at 1-800-FDA-1088 or www.fda.gov.medwatch. AEs clinical trials
Pharmacokinetics
The 1-hydroxy metabolite is approximately 89% bound to plasma protein Elimination Elimination of the parent drug takes place via hepatic metabolism of midazolam to hydroxylated metabolites that are conjugated and excreted in the urine.
The principal urinary excretion products are glucuronide conjugates of the hydroxylated derivatives.
Excretion Following IM administration of 10 mg midazolam via this autoinjector, mean (±SD) terminal elimination halflife was 5.16 (±1.77) hours and mean (±SD) apparent total body clearance (CL/F) of midazolam was and 23.8 (±6.77) L/hr.
The principal urinary excretion product is 1-hydroxy-midazolam in the form of a glucuronide conjugate; smaller amounts of the glucuronide conjugates of 4-hydroxy- and dihydroxy-midazolam are detected as well.
The amount of midazolam excreted unchanged in the urine after a single IV dose is less than 0.5%.
Pharmacokinetics (US label) US FDA label
Mechanism of Action The exact mechanism of action for midazolam in the treatment of status epilepticus is not fully understood, but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. Pharmacodynamics The effects of midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications.
Pharmacokinetics The pharmacokinetics of midazolam were evaluated in a single dose-escalation trial in healthy subjects; following IM injection of midazolam at doses ranging from fixed total amounts of 5 mg to 30 mg (one half to three times the recommended dose) or body weight based dose of 0.10 mg/kg to 0.49 mg/kg, the overall median time to maximum plasma concentration (Tmax) was observed at approximately 0.5 hours after administration. The rate and extent of systemic exposure, as assessed by maximum plasma concentration (Cmax) and area under the plasma drug concentration-time curve from time 0 to infinity (AUC0-∞), tended to increase proportionally with increasing dose from 5 mg to 30 mg.
Absorption Following IM administration of a single 10 mg midazolam dose to healthy subjects via this autoinjector, midazolam was absorbed with median Tmax (range) of 0.5 (0.17 to 1.03) hours; midazolam mean (±SD) Cmax and AUC 0-∞ were 127 (±47.3) ng/mL and 454 (±134) ng∙hr/mL, respectively. Distribution The mean (±SD) apparent volume of distribution (Vz/F) of midazolam following a single IM dose of 10 mg midazolam via this autoinjector was 169 (±61.7) L in healthy subjects.
In humans, midazolam has been shown to cross the placenta and enter into fetal circulation, and has been detected in human milk and CSF [see Use in Specific Populations (8.1, 8.2)]. In adults, midazolam is approximately 97% bound to plasma protein, principally albumin. The 1-hydroxy metabolite is approximately 89% bound to plasma protein Elimination Elimination of the parent drug takes place via hepatic metabolism of midazolam to hydroxylated metabolites that are conjugated and excreted in the urine.
Metabolism In vitro studies with human liver microsomes indicate that the biotransformation of midazolam is mediated by the cytochrome P450-3A4 (CYP3A4). This enzyme is present in gastrointestinal tract mucosa, as well as in the liver. The 1-hydroxy-midazolam (also termed alpha-hydroxymidazolam) metabolite comprises 60% to 70% of the biotransformation products of midazolam, while 4-hydroxy-midazolam constitutes 5% or less.
Small amounts of a dihydroxy derivative have also been detected, but not quantified. The principal urinary excretion products are glucuronide conjugates of the hydroxylated derivatives. Studies of the intravenous administration of 1-hydroxy-midazolam in humans suggest that 1-hydroxymidazolam is at least as potent as the parent compound, and may contribute to the net pharmacologic activity of midazolam.
In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. Excretion Following IM administration of 10 mg midazolam via this autoinjector, mean (±SD) terminal elimination halflife was 5.16 (±1.77) hours and mean (±SD) apparent total body clearance (CL/F) of midazolam was and 23.8 (±6.77) L/hr.
The principal urinary excretion product is 1-hydroxy-midazolam in the form of a glucuronide conjugate; smaller amounts of the glucuronide conjugates of 4-hydroxy- and dihydroxy-midazolam are detected as well. The amount of midazolam excreted unchanged in the urine after a single IV dose is less than 0.5%. Following a single IV infusion in 5 healthy volunteers, 45% to 57% of the dose was excreted in the urine as the 1-hydroxymethyl midazolam conjugate.
Specific Populations Changes in the pharmacokinetic profile of midazolam due to drug interactions, physiological variables, etc., may result in changes in the plasma concentration-time profile and pharmacological response to midazolam in these patients. For example, patients with acute renal failure (ARF) appear to have a longer elimination half-life for midazolam [see Use in Specific Populations (8.6)].
In other groups, the relationship between prolonged half-life and duration of effect has not been established. Obesity In a study comparing normal (n=20) and obese patients (n=20), the mean half-life was greater in the obese group (5.9 versus 2.3 hours). This was due to an increase of approximately 50% in the volume of distribution (Vd) corrected for total body weight.
The clearance was not significantly different between groups. Geriatric Patients In three parallel-group studies, the pharmacokinetics of midazolam administered IV or IM were compared in young (mean age 29 years, n=52) and healthy elderly subjects (mean age 73 years, n=53). Plasma half-life was approximately 2-fold higher in the elderly.
The mean Vd based on total body weight increased consistently between 15% and 100% in the elderly. The mean CL (total clearance) decreased approximately 25% in the elderly in two studies, and was similar to that of the younger patients in the other [see Use in Specific Populations (8.5)]. Male and Female Patients No meaningful differences in midazolam exposures (C max and AUC) were observed between male and female adults after IM administration.
Patients with Congestive Heart Failure In patients suffering from congestive heart failure, a 2-fold increase in the elimination half-life, a 25% decrease in the plasma clearance, and a 40% increase in the volume of distribution of midazolam were observed. Patients with Renal Impairment Patients with renal impairment may have longer elimination half-lives for midazolam and its metabolites [see Use in Specific Populations (8.6)].
Midazolam and 1-hydroxy-midazolam pharmacokinetics were compared between 6 intensive care unit (ICU) patients who developed acute renal failure (ARF) and a control group of subjects with normal renal function. Midazolam was administered as an IV infusion (5 to 15 mg/hour). Midazolam clearance was reduced (1.9 versus 2.8 mL/min/kg), and the half-life was prolonged (7.6 hours versus 13 hours) in the ARF patients.
The renal clearance of the 1-hydroxy-midazolam glucuronide was prolonged in the ARF group (4 versus 136 mL/min), and the half-life was prolonged (12 hours versus >25 hours). Plasma levels accumulated in all ARF patients to about ten times that of the parent drug. The relationship between accumulating metabolite levels and prolonged sedation is unclear.
In a study of chronic renal failure patients (n=15) receiving a single IV dose of midazolam, there was a 2-fold increase in the clearance and volume of distribution, but the half-life remained unchanged. Metabolite levels were not studied. Patients with Hepatic Impairment Midazolam pharmacokinetics were studied after a single IV dose (0.075 mg/kg) was administered to 7 patients with biopsy-proven alcoholic cirrhosis and 8 control patients.
The mean half-life of midazolam increased 2.5-fold in the patients with cirrhosis. Clearance was reduced by 50% and Vd increased by 20%. In another study in 21 male patients with cirrhosis, without ascites and with normal kidney function as determined by creatinine clearance, no changes in the pharmacokinetics of midazolam or 1-hydroxy-midazolam were observed when compared to healthy individuals.
The clinical significance of these findings is unknown. Drug Interaction Studies CYP3A4 Inhibitors Drugs that inhibit the activity of CYP3A4 may inhibit midazolam clearance and elevate midazolam concentrations [see Drug Interactions (7.3)]. The effect of single oral doses of 800 mg cimetidine and 300 mg ranitidine on steady-state concentrations of oral midazolam was examined in a randomized crossover study (n=8).
Cimetidine increased the mean midazolam steady-state concentration from 57 to 71 ng/mL. Ranitidine increased the mean steady-state concentration to 62 ng/mL. No change in choice reaction time or sedation index was detected after dosing with the H2 receptor antagonists. In a placebo-controlled study, erythromycin administered as a 500 mg dose, three times a day, for 1 week (n=6), reduced the clearance of midazolam following a single 0.5 mg/kg IV dose.
The half-life was approximately doubled. The effects of diltiazem (60 mg three times a day) and verapamil (80 mg three times a day) on the pharmacokinetics and pharmacodynamics of midazolam were investigated in a three-way crossover study (n=9). The half-life of midazolam increased from 5 to 7 hours when midazolam was taken in conjunction with verapamil or diltiazem.
No interaction was observed in healthy subjects between midazolam and nifedipine. In a placebo-controlled study, where saquinavir or placebo was administered orally as a 1200 mg dose three times a day for 5 days (n=12), a 56% reduction in the clearance of midazolam following a single 0.05 mg/kg IV dose was observed. The half-life was approximately doubled.
CYP3A4 Inducers Drugs that induce the activity of CYP3A4 may increase midazolam clearance and decrease midazolam concentrations.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Midazolam 1 mg/mL, 5 mL Ampule | ₱59.00–₱91.00Reference ₱70.00 | per ampule | DPRI procurement range |
| Midazolam 5 mg/mL, 3 mL Ampule | ₱88.89–₱215.84Reference ₱104.89 | per ampule | DPRI procurement range |
| Midazolam 5 mg/mL,1 mL Ampule ● | ₱49.74–₱159.00Reference ₱61.40 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Midazolam |
| PNF listing | Oral: 15 mg tabletRestrictions: Dangerous drug: DOH Official Prescription Form (yellow Rx), S2 license, no refill (PNF code A1) |
| PNF listing | Inj.: 1 mg/mL, 5 mL ampul/vial (IM, IV)Restrictions: Dangerous drug: DOH Official Prescription Form (yellow Rx), S2 license, no refill (PNF code A1) |
| PNF listing | Inj.: 5 mg/mL, 1 mL, 2 mL, 3 mL, 5 mL and 10 mL ampul (IM, IV)Restrictions: Dangerous drug: DOH Official Prescription Form (yellow Rx), S2 license, no refill (PNF code A1) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. N/A · Rafa Laboratories, Ltd. [US FDA-approved label, version 5, February 18, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7362b4d-68a3-99a0-e053-2995a90a4f60
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .